Back to results
US 7,670,769 B2Granted
IL1RL-1 as a cardiovascular disease marker and therapeutic target
AssigneeThe Brigham and Women's Hospital, Inc.
InventorRichard T. Lee
Life of this patent
Estimating the term…
Abstract
This invention pertains to methods and compositions for the diagnosis and treatment of cardiovascular conditions. More specifically, the invention relates to isolated molecules that can be used to diagnose and/or treat cardiovascular conditions including cardiac hypertrophy, myocardial infarction, stroke, arteriosclerosis, and heart failure.
Claims42
A method for predicting outcome of a cardiovascular condition, comprising:
- obtaining a level of an IL1RL-1 molecule in a subject having or suspected of having a cardiovascular condition by contacting a biological sample from the subject with an agent, wherein the agent specifically binds to the IL1RL-1molecule, and
- comparing the level of the IL1RL-1 molecule to a predetermined value specific for predicting outcome of the cardiovascular condition, wherein the level of the IL1RL-1 molecule in comparison to the predetermined value is indicative of the outcome of the cardiovascular condition, and wherein an increased level in comparison to the predetermined value is indicative of a negative outcome and a decreased level is indicative of a positive outcome.
A method for predicting outcome of a cardiovascular condition, comprising:
- obtaining a first level of an IL1RL-1 molecule in a subject having or suspected of having a cardiovascular condition by contacting a first biological sample from the subject with a first agent, wherein the first agent specificaly binds to the IL1RL-1 molecule,
- obtaining a second level of the IL1RL-1 molecule in the subject having or suspected of having a cardiovascular condition by contacting a second biological sample from the subject with a second agent, wherein the second agent specifically binds to the IL1RL-1 molecule, and
- comparing the change in the levels of the IL1RL-1 molecule to a predetermined value specific for predicting outcome of the cardiovascular condition, wherein the change in the levels of the IL1RL-1 molecule in comparison to the predetermined value is indicative of the outcome of the cardiovascular condition.
Dependencies are inferred from the claim text.